PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice

beta-Thalassaemia major is an inherited blood disorder which is complicated by repeated blood transfusion and excessive gastrointestinal iron (Fe) absorption, which leads to toxic Fe overload. Current treatment using the chelator, desferrioxamine (DFO), is expensive and cumbersome since the drug requires long subcutaneous infusions and it is not orally active. A novel chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone (PCTH), was recently designed and shown to have high Fe chelation efficacy in vitro. The aim of this investigation was to examine the Fe chelation efficacy of PCTH in vitro implementing primary cultures of cardiomyocytes and in vivo using mice. We showed that PCTH was significantly (P<0.005) more effective than DFO at mobilising (59)Fe from prelabelled cardiomyocytes. Moreover, PCTH prevented the incorporation of (59)Fe into ferritin during Fe uptake from (59)Fe-labelled transferrin. These effects were important to assess as cardiac complications caused by Fe deposition are a major cause of death in beta-thalassaemia major patients. Further studies showed that PCTH was orally active and well tolerated by mice at doses ranging from 50 to 200 mg/kg, twice daily (bd), for 2 days. A dose-dependent increase in faecal (59)Fe excretion was observed in the PCTH-treated group. This level of Fe excretion at 200 mg/kg was similar to the same dose of the orally effective chelators, pyridoxal isonicotinoyl hydrazone (PIH) and deferiprone (L1). Effective Fe chelation in the liver by PCTH was shown via its ability to reduce ferritin-(59)Fe accumulation. Mice treated for 3 weeks with PCTH at doses of 50 and 100 mg/kg/bd showed no overt signs of toxicity as determined by weight loss and a range of biochemical and haematological indices. In subchronic Fe excretion studies over 3 weeks, PIH and PCTH at 75 mg/kg/bd for 5 days/week increased faecal (59)Fe excretion to 140% and 145% of the vehicle control, respectively. This study showed that PCTH was well tolerated at 100 mg/kg/bd and induced considerable Fe excretion by the oral route, suggesting its potential as a candidate to replace DFO.     

Kinetics of arsenic(III) oxidation by iron(III) catalysed by pyrite in the presence ofThiobacillus ferrooxidans

Summary A simple kinetic model of As(III) oxidation by Fe(III) in the presence of pyrite andThiobacillus ferroxidans is described based on the stoichiometry of the reaction and bioproduction of Fe(III). The environmental consequences of this reaction were considered.     

HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study

A high performance liquid chromatographic method for the determination of a biocompatible iron chelator, pyridoxal 2-chlorobenzoyl hydrazone (o-108), in rabbit plasma was developed and validated. The separation was achieved on a C18 column with the mobile phase composed of a mixture of 0.01 M phosphate buffer (pH 6) with the addition of EDTA (2 mM), methanol and acetonitrile (42:24:14; v/v/v). The method was validated with respect to selectivity, linearity (0.8-150 microg/mL), intra- and inter-day variability and stability. This method was successfully applied to the analysis of the samples obtained from a pilot pharmacokinetic experiment, in which the chelator was administered intravenously to rabbits.     

Some iron(III) complexes with polydentate Schiff base ligands

The iron(III) complexes of three Schiff base ligands are studied as their chloride or perchlorate salts and their electronic spectra, EPR spectra, and electrochemical behavior reported. Two of these ligands are formed from reaction between salicylaldehyde and 9 or 12-membered tri- or tetraazalkanes. EPR evidence indicates that one of the complexes, [1,12-bis(2-hydroxybenzylidene)-(1,4,9,12-tetraazadodec- 6-ene)iron(III)]perchlorate-1,5-water, is a spin-crossover species containing both high-spin and low-spin iron(III) in equilibrium. The third ligand comes from pyrrole-2-carboxaldehyde and a tetraazadodecane.     

High-spin Schiff-base dinuclear iron(III) complexes bridged by N-oxide ligands

Synthesis and structure of dinuclear complexes [{Fe^III(L⁵)}b{Fe^III(L⁵)}](BPh₄)₂, where L⁵ is a pentadentate Schiff-base ligand, b is a bidentate N-oxide bridging ligand based on bipyridine, is reported. Magnetic behavior is investigated in terms of the magnetic susceptibility, magnetization, and Mössbauer spectroscopy revealing that the complexes are high-spin over the whole temperature region.     

Partition coefficients of the iron(III) complexes of pyridoxal isonicotinoyl hydrazone and its analogs and the correlation to iron chelation efficacy

Pyridoxal isonicotinoyl hydrazone and its analogs are orally effective Fe(III) chelators which show potential as drugs to treat iron overload disease. The present investigation describes the measurement of the partition coefficient of the apochelator and Fe(III) complex of 20 of these ligands. These measurements have been done to investigate the relationship between lipophilicity and the efficacy of iron chelation in rabbit reticulocytes loaded with non-heme ⁵⁹Fe. The results demonstrate a linear relationship between the partition coefficient (P) of the apochelator and its Fe(III) complex, and a simple equation has been derived relating these two parameters. Experimental data in the literature are in agreement with the equation. The relationship of the partition coefficients of the iron chelators and of their Fe(III) complexes to the effectiveness of the ligands in mobilizing iron in vitro and in vivo is also discussed.     

Chemistry and reactivity of dinuclear iron oxamate complexes: alkane oxidation with hydrogen peroxide catalysed by an oxo-bridged diiron(III) complex with amide and carboxylate ligation

A new dinuclear iron(III) complex with the tetradentate ligand N,N^′-o-phenylenebis(oxamate) (opba) has been synthesised, and structurally, magnetically and electrochemically characterised. It possesses an unprecedented triply bridged Fe₂(μ-O)(μ-RCO₂?H₂O?O₂CR)₂ core, whereby two N-amides from the opba ligand complete the square-pyramidal coordination sphere of the O-carboxylate rich iron site (Fe-N=2.053 Å and Fe-O=2.015 Å). The antiferromagnetic exchange interaction between the two high-spin Fe^III ions through the oxo bridge (J=−190 cm⁻¹; H=−JS₁·S₂) is weaker than that found in related μ-oxo singly bridged diiron(III) complexes. The lessened antiferromagnetic coupling correlates to the remarkably long Fe-O distance (R=1.808 Å), which is associated to the relatively bent Fe-O-Fe angle (α=131.8°) in the Fe₂O unit. It experiences an irreversible one-electron oxidation process in acetonitrile at 25 °C (E=0.63 V versus SCE) to give the putative mixed-valent diiron(III,IV) species which is unstable under the experimental conditions. The reactivity of this unique oxo-bridged diiron(III) oxamate complex toward hydrogen peroxide activation and hydrocarbon oxidation in the presence of dioxygen has been examined. It catalyses the oxidation of alkanes like cyclohexane and adamantane to the corresponding alcohols and ketones by H₂O₂ and O₂ in acetonitrile at room temperature with limited catalytic activities (total yields of ca. 5% after 24 h) and modest selectivities (A/K=0.9, KIE=2.4, tert/sec=3.0). Overall, these results are more in line with a mechanism involving alkyl radicals as transient intermediates, although they do not exclude the possibility that a metal-based active oxidant is also involved in this C-H bond oxidation chemistry.     

Octanuclear iron(III) complexes supported by Kemp’s tricarboxylate ligands

Reactions of FeCl₂·4H₂O and diimino ligand (L) with H₃kta (cis,cis-1,3,5-trimethylcyclohexane-1,3,5-tricarboxylic acid) in the presence of [ⁿBu₄N][OH] afforded a series of octanuclear iron(III) complexes formulated as [Fe₈O₅(kta)₂(Hkta)₄(L)₂] (L = bpy (1), 5,5′-Me₂bpy (2), 4,4′-Me₂bpy (3), phen (4), 4-Mephen (5), 4,7-Me₂phen (6), and 3,4,7,8-Me₄phen (7)). The structure of 4 was determined by X-ray crystallography to consist of a planar {Fe₈(μ₄-O)(μ₃-O)₄}¹⁴⁺ core supported by two kta³⁻ tricarboxylates, where the inner four Fe^III ions form a {Fe₄O₅} square plane, of which apex μ-oxo atoms are further connected to the outer four Fe^III ions. The peripheral part of the Fe₈ core is bridged by four Hkta²⁻ ligands and chelated by two phen ligands. ⁵⁷Fe Mössbauer spectra of 2 at 290 K and 77 K indicated the presence of high-spin octahedral Fe(III) ions, and the temperature dependent dc magnetic susceptibility data for 1, 2, and 4 showed strong antiferromagnetic exchange in the {Fe₈O₅} moiety.     

Studies on biologically active complexes of cobalt(II) and nickel(II) with dithiooxamide-derived ligands.

A number of cobalt(II) and nickel(II) complexes with novel dithiooxamide ligands derived from precursors such as benzonitrile, benzosulfonamide, benzaldehyde, benzoic acid, and phenol have been synthesized and characterized on the basis of their elemental analysis molar conductance, magnetic moment, H NMR and electronic and IR spectral data. These ligands and their complexes have been screened for their antibacterial activities against bacterial species Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, and Tuberculi bacilli. The studies indicate that in comparison to the ligands their metal complexes are more potent and antibacterial.     

Interaction between iron(II) and hydroxamic acids: oxidation of iron(II) to iron(III) by desferrioxamine B under anaerobic conditions

Interaction between iron(II) and acetohydroxamic acid (Aha), alpha-alaninehydroxamic acid (alpha-Alaha), beta-alaninehydroxamic acid (beta-Alaha), hexanedioic acid bis(3-hydroxycarbamoyl-methyl)amide (Dha) or desferrioxamine B (DFB) under anaerobic conditions was studied by pH-metric and UV-Visible spectrophotometric methods. The stability constants of complexes formed with Aha, alpha-Alaha, beta-Alaha and Dha were calculated and turned out to be much lower than those of the corresponding iron(II) complexes. Stability constants of the iron(II)-hydroxamate complexes are compared with those of other divalent 3d-block metal ions and the Irving-Williams series of stabilities was found to be observed. Above pH 4, in the reactions between iron(II) and desferrioxamine B, the oxidation of the metal ion to iron(III) by the ligand was found. The overall reaction that resulted in the formation of the tris-hydroxamato complex [Fe(HDFB)]+ and monoamide derivative of DFB at pH 6 is: 2Fe2+ + 3H4DFB+ = 2[Fe(HDFB)]+ + H3DFB-monoamide+ + H2O + 4H+. Based on these results, the conclusion is that desferrioxamine B can uptake iron in iron(III) form under anaerobic conditions.     

Comparison of iron chelator efficacy in iron-overloaded beagle dogs and monkeys (Cebus apella)

Rodents and dogs are frequently used for preclinical toxicologic assessment of candidate iron chelators. Although the iron-clearing profile of a ligand often is known in rodents, and sometimes in primates, such information in dogs is rarely, if ever, available. Because of this, toxicity studies in dogs could be misleading; chelators that may otherwise be suitable for human clinical studies may be abandoned as being unacceptably toxic, simply because, unknown to the investigator, these drugs remove more iron in this species than would have been expected on the basis of iron clearance results in other species. This is a scenario that we encountered during toxicity trials of (S)-beta,beta-dimethyl-4'-hydroxydesazadesmethyldesferrithiocin in dogs. Thus, we developed an iron-overloaded dog model in which it is possible to evaluate iron-clearing efficiencies of potential therapeutic ligands. Seven deferration agents have been screened in this model, and the results were compared with the iron-clearing efficiency of the same ligands in an iron-loaded Cebus apella monkey model. The data suggest that while the iron-clearing efficiencies of most of the drugs were similar between the two species, there can be profound differences. This is consistent with the idea that caution needs to be exercised when carrying out preclinical toxicity evaluations of a chelator in dogs without first measuring the drug's iron-clearing efficiency in this species.     

Hydrogen bonding in diruthenium(II,III) tetraacetate complexes with biologically relevant axial ligands

Three diadduct complexes of the mixed-valent form of diruthenium tetraacetate, [Ru₂(μ-O₂CCH₃)₄L₂](PF₆), where L are the biologically relevant ligands imidazole, 1, 7-azaindole, 2, and caffeine, 3, were synthesized and characterized by elemental analysis, IR and UV-Vis spectroscopy and X-ray crystallography. In order to further elucidate the potential interactions of these dimers with DNA, the nature of the ligand coordination and the secondary inter- and intramolecular hydrogen-bonding interactions in all three complexes were assessed. Complex 1 · CH₂Cl₂ shows, exclusively, intermolecular interactions with the counterion whereas complexes 2 · ClCH₂CH₂Cl and 3 · OC(CH₃)₂ · H₂O, in addition to extensive intermolecular interactions, show intramolecular hydrogen bonding from the axial ligand to the bridging acetate oxygens, locking the ligand mean planes in place between the bridging acetate mean planes. In addition, all three complexes display π-π stacking of axial ligand rings on adjacent diadduct units.     

The orientation of the ligands in iron(III)-bleomycin intercalated with DNA

EPR data show that Fe(III)-bleomycin intercalates with DNA, or that the Fe(III) coordination sphere has a fixed geometrical configuration with respect to the DNA helical axis. An analysis of the data from oriented DNA fibers, drawn from a viscous gel, shows that the angle between the fiber axis and the normal to a plane containing the Fe(III) ion and ligands ranges between 15 and 30 degrees. The principal g values for the low-spin Fe(III)-bleomycin-DNA complex at pH 7.5 are 2.45, 2.18 and 1.87     

Synthesis and characterization of tetraphenylporphyrin iron(III) complexes with substituted phenylcyanamide ligands

Several five coordinate complexes of [(TPP)Fe^III(L)] in which TPP is the dianion of tetraphenylporphyrin and L is the monoanion of phenylcyanamide (pcyd) (1), 2,5-dichlorophenylcyanamide (2,5-Cl₂pcyd) (2), 2,6-dichlorophenylcyanamide (2,6-Cl₂pcyd) (3), and 2,3,4,6-tetrachlorophenylcyanamide (2,3,4,6-Cl₄pcyd) (4) have been prepared by the reaction of [(TPP)Fe^IIICl] with appropriate thallium salt of phenylcyanamide. Each of the complexes has been characterized by IR, UV-Vis and ¹H NMR spectroscopic data. Dark red-brown needles of [(TPP)Fe^III(2,6-Cl₂pcyd)] (C₅₁H₃₁Cl₂FeN₆ · CHCl₃) crystallize in the triclinic system. The crystal structure of Fe(III) compound shows a slight distortion from square pyramidal coordination with the 2,6-dichlorophenylcyanamide anion in the axial position through nitrile nitrogen atom. Iron atom is 0.47(1) Å out of plane of the porphyrin toward phenylcyanamide ligand. In non-coordinating solvents, such as benzene or chloroform, these complexes exhibit ¹H NMR spectra that are characteristic of high-spin (S = 5/2) species. The X-ray crystal structure parameters are also consistent with high-spin iron(III) complexes. The iron(III) phenylcyanamide complexes are not reactive toward molecular oxygen; however, these complexes react with HCl and produce TPPFe^IIICl.     

The orientation of the ligands in iron(III)-bleomycin intercalated with DNA

EPR data show that Fe(III)-bleomycin intercalates with DNA, or that the Fe(III) coordination sphere has a fixed geometrical configuration with respect to the DNA helical axis. An analysis of the data from oriented DNA fibers, drawn from a viscous gel, shows that the angle between the fiber axis and the normal to a plane containing the Fe(III) ion and ligands ranges between 15 and 30 degrees. The principal g values for the low-spin Fe(III)-bleomycin-DNA complex at pH 7.5 are 2.45, 2.18 and 1.87.     

Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity

 Previous studies have demonstrated that 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and several other aroylhydrazone chelators possess anti-neoplastic activity due to their ability to bind intracellular iron. In this study we have examined the structure and properties of NIH and its Fe^III complex in order to obtain further insight into its anti-tumour activity. Two tridentate NIH ligands deprotonate upon coordination to Fe^III in a meridional fashion to form a distorted octahedral, high-spin complex. Solution electrochemistry of [Fe(NIH–H)₂]⁺ shows that the trivalent oxidation state is dominant over a wide potential range and that the Fe^II analogue is not a stable form of this complex. The fact that [Fe(NIH–H)₂]⁺ cannot cycle between the Fe^II and Fe^III states suggests that the production of toxic free-radical species, e.g. OH ^. or O₂ ^{. –}, is not part of this ligand's cytotoxic action. This suggestion is supported by cell culture experiments demonstrating that the addition of Fe^III to NIH prevents its anti-proliferative effect. The chemistry of this chelator and its Fe^III complex are discussed in the context of understanding its anti-tumour activity. Received: 12 November 1998 / Accepted: 9 February 1999     

Ligational behavior of a novel biologically active donor toward Cu(II) and Ni(II) ions and potentiation of its antibacterial activity by chelation with metal ions

The chelating behavior of a new multidentate ligand with tuberculostatic activity toward Cu(II) and Ni(II) ions has been studied. This ligand 3-(2-carboxyhydrazine)phenylimino-2-oximobutane(H2C POB) is found to chelate the above metal ions in both its keto and enol forms. The probable structures of all the complexes and the location of the bonding sites have been established through magnetic and spectroscopic (infrared, electronic) studies. The Cu(II) complex of the enol form exhibits subnormal magnetic moment at room temperature, indicating the probable existence of some sort of super exchange phenomenon in the system. The ligand itself and a few of its Cu(II) complexes have been found to exert powerful in vitro antibacterial activity toward some tuberculosis mycobacteria, such as Mycobacterium flae, Mycobacterium smegmatis, and Mycobacterium H37Rv.     

Probucol protects against hypochlorite-induced endothelial dysfunction: identification of a novel pathway of probucol oxidation to a biologically active intermediate

Atherosclerosis is associated with endothelial dysfunction and a heightened state of inflammation characterized, in part, by an increase in vascular myeloperoxidase and proteins modified by its principal oxidant, hypochlorous acid (HOCl). Here we examined whether probucol could protect against endothelial dysfunction induced by the two-electron oxidant HOCl. Hypochlorous acid eliminated endothelium-dependent relaxation of rabbit aorta, whereas endothelial function and tissue cGMP was preserved and elevated, respectively, in animals pretreated with probucol. Exogenously added probucol also protected against HOCl-induced endothelial dysfunction. In vitro, HOCl oxidized probucol in a two-phase process with rate constants k(1) = 2.7 +/- 0.3 x 10(2) and k(2) = 0.7 +/- 0.2 x 10(2) m(-1) s(-1) that resulted in a dose- and time-dependent accumulation of probucol-derived disulfoxide, 4,4'-dithiobis(2,6-di-tert-butyl-phenol) (DTBP), DTBP-derived thiosulfonate, disulfone, and sulfonic acid, together with 3,3',5,5'-tetra-tert-butyl-4,4'-diphenoquinone (DPQ) as determined by high performance liquid chromatography and mass spectrometry. Like HOCl, selected one-electron oxidants converted probucol into DTBP and DPQ. Also, dietary and in vitro added DTBP protected aortic rings from HOCl-induced endothelial dysfunction and in vitro oxidation by HOCl gave rise to the thiosulfonate, disulfone, and sulfonic acid intermediates and DPQ. However, the product profiles of the in vitro oxidation systems were different from those in aortas of rabbits receiving dietary probucol or DTBP +/- HOCl treatment. Together, the results show that both probucol and DTBP react with HOCl and protect against HOCl-induced endothelial dysfunction, although direct scavenging of HOCl is unlikely to be responsible for the vascular protection by the two compounds.     

Ligational behavior of two biologically active N-S donors toward oxovanadium(IV) ion and potentiation of their antibacterial activities by chelation to metal ions. Part III

Chelating behavior of two biologically active ligands, pyridine-2-carboxaldehyde thiosemicarbazone (PT) and pyridine-2-carboxaldehyde-(4-phenyl)thiosemicarbazone (PPT), toward oxovanadium(IV) ion has been studied. The ligands are found to react in the thioketo form (pH 2-4), yielding the complexes [VO(PT)X2](X = Cl-, Br-, ClO4-), [VO(PT)(SO4)H2O], [VO(PPT)2X]X (X = Cl-, Br-, ClO4-) and [VO(PPT)2SO4]. Reactions of [VO(PT)(SO4)H2O] and [VO(PPT)2X]X (X = Cl-, Br-, ClO4-) with a monodenate Lewis base (B) like pyridine lead to the formation of [VO(PT)(SO4)Py]H2O and [VO(PPT)2py]X2 respectively. Bonding sites of the donor molecules around the oxometal cation have been located. Nature of the EPR spectra and magnetic moment values point to the monomeric character of the complexes and suggest a distorted octahedral donor environment for the oxovanadium(IV) ion. Status of the metal-oxygen multiple bond in all the complexes has been computed in terms of the V-O(1) stretching force constant. The ligands themselves and most of their oxovanadium(IV) complexes are found to exert powerful in vitro antibacterial activities towards E. coli.